Success Metrics

Active Trials

0(0%)

Phase Distribution

Ph phase_1

57%

Ph phase_2

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

4(57.1%)

Phase 2Efficacy & side effects

3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Other(7)

Detailed Status

unknown7

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 14 (57.1%)

Phase 23 (42.9%)

Trials by Status

unknown7100%

Recent Activity

0 active trials

Showing 5 of 7

unknownphase_1

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

NCT04615468

unknownphase_2

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

NCT04398953

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT03510767Phase 1

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Unknown

NCT05675202Phase 1

Material Balance Study of TQ-B3525

Unknown

NCT04690725Phase 1

TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss

Unknown

NCT04615468Phase 2

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

Unknown

NCT04398953Phase 2

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Unknown

NCT04324879Phase 2

A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Unknown

NCT04355520Phase 1

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Unknown

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7